{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:34:19Z","timestamp":1787726059977,"version":"build-2784847793"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of Conbercept, Ranibizumab, and Aflibercept, alone or combined with laser, for the treatment of diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Cochrane Library, Embase, Web of Science, CNKI, WanFang, and SinoMed until October 2024 for studies on Conbercept, Ranibizumab, and Aflibercept in DME treatment. Bayesian network meta-analysis was conducted in RStudio. Study quality was assessed with the Cochrane ROB.2 and the Confidence in Network Meta-Analysis framework. This study was registered with PROSPERO (CRD42024608409).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 64 randomized controlled trials, including 7,185 patients, were analyzed in this study. Results indicated that Ranibizumab\u2009+\u2009laser yielded the most significant improvement in central retinal thickness (CRT) at 3 months (MD \u221280.98, 95% CI \u2212106.53, \u221255.64; SUCRA 81.92%), 6 months (\u221290.19, [\u2212126.05, \u221254.77]; 81.62%), and 12 months (\u2212134.99, [\u2212194.2, \u221275.98; 87.56%). Conbercept\u2009+\u2009laser (3 months: \u221252.47, [\u221280.7, \u221224.14]; 6 months: \u221252.98, [\u221294.72, \u221211.02]) and Ranibizumab monotherapy (3 months: \u221264.45,[\u2212101.28, \u221226.77]) also showed statistically significant CRT reductions compared to laser alone, though to a lesser degree than Ranibizumab\u2009+\u2009laser. For Best-Corrected Visual Acuity (BCVA), both Ranibizumab and Ranibizumab\u2009+\u2009laser achieved statistically significant gains at 6 and 12 months compared to laser alone, with Ranibizumab\u2009+\u2009laser consistently ranking highest in efficacy. Safety analysis revealed no significant differences in total adverse event rates across treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ranibizumab\u2009+\u2009laser therapy demonstrated the greatest improvement in CRT and BCVA at 3, 6, and 12 months, with no significant differences in adverse events compared to other anti-VEGF options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251350017","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:41:26Z","timestamp":1751337686000},"page":"2347-2360","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and safety of anti-VEGF agents with and without Laser therapy for diabetic macular edema: A network meta-analysis"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3403-1473","authenticated-orcid":false,"given":"Lin","family":"Chen","sequence":"first","affiliation":[{"name":"Foshan Hospital of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Chen","sequence":"additional","affiliation":[{"name":"Foshan Hospital of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Huang","sequence":"additional","affiliation":[{"name":"Shenzhen traditional Chinese Medicine Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i1.92"},{"key":"e_1_3_3_3_2","article-title":"Overview of diabetic macular edema[J]","volume":"22","author":"Holekamp NM","year":"2016","unstructured":"Holekamp NM. Overview of diabetic macular edema[J]. Am J Manag Care 2016; 22: s284\u2013s291.","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103148"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.006"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20190129-02"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119857511"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2156273"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9718-9"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.47.31283"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.599281"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.09.002"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19204"},{"key":"e_1_3_3_16_2","article-title":"Diabetic retinopathy preferred practice pattern\u00ae [published correction appears in Ophthalmology. 2020 Sep;127(9):1279. doi: 10.1016\/j.ophtha.2020.06.047]","volume":"127","author":"Flaxel CJ","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern\u00ae [published correction appears in Ophthalmology. 2020 Sep;127(9):1279. doi: 10.1016\/j.ophtha.2020.06.047]. Ophthalmology 2020; 127: P66\u2013P145.","journal-title":"Ophthalmology"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2641"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.09.17"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0035-x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637667"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0554-8"},{"issue":"17","key":"e_1_3_3_23_2","first-page":"83","article-title":"Observation of the efficacy of conbercept combined with 577 nm micropulse laser in the treatment of diabetic macular edema","volume":"8","author":"He C","year":"2018","unstructured":"He C, Zou Q, Cao K, et al. Observation of the efficacy of conbercept combined with 577 nm micropulse laser in the treatment of diabetic macular edema. Front Med 2018; 8(17): 83\u201384. doi:https:\/\/doi.org\/10.3969\/j.issn.2095-1752.2018.17.056.","journal-title":"Front Med"},{"key":"e_1_3_3_24_2","first-page":"259","article-title":"Effects of intravitreal injection of ranibizumab and conbercept on vision and macular thickness in patients with diabetic macular edema","volume":"40","author":"Yang X","year":"2020","unstructured":"Yang X, Song Y, Zhang D. Effects of intravitreal injection of ranibizumab and conbercept on vision and macular thickness in patients with diabetic macular edema. Harbin Med 2020; 40: 259\u2013260.","journal-title":"Harbin Med"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2014.12.014"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-019-01280-9"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_3_28_2","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J 2019; 366: l4898. Published 2019 Aug 28.","journal-title":"Br Med J"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"key":"e_1_3_3_30_2","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou T","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 2020; 16: e1080. Published 2020 Mar 11.","journal-title":"Campbell Syst Rev"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/096228029600500402"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys041"},{"key":"e_1_3_3_33_2","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials","volume":"376","author":"Chawla N","unstructured":"Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. Br Med J 2022 Jan 19; 376: e066084. PMID: 35045991; PMCID: PMC8767458.","journal-title":"Br Med J"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu424"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251350017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251350017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251350017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:54:21Z","timestamp":1784019261000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251350017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/11206721251350017"],"URL":"https:\/\/doi.org\/10.1177\/11206721251350017","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}